Background The efficacy and safety of rivaroxaban have been demonstrated in phase 3
trials of patients with venous thromboembolism (VTE; pulmonary embolism [PE] and deep …

Background: There is insufficient real-world data on the current status of Japanese patients
with venous thromboembolism (VTE) or its treatment and prevention with rivaroxaban …

Background: The incidence of venous thromboembolism (VTE; pulmonary embolism [PE]
and/or deep vein thrombosis [DVT]) in Japan is increasing, but relatively small numbers of …

Objective Rivaroxaban is commonly prescribed to prevent venous thromboembolism (VTE).
Although lower than standard dosages (under-dosing) may be administered in the real …

Abstract Background The global EINSTEIN DVT and PE studies compared rivaroxaban (15
mg twice daily for 3 weeks followed by 20 mg once daily) with enoxaparin/vitamin K …

Data on long-term effectiveness and safety of venous thromboembolism (VTE) treatment
with rivaroxaban are scarce and not available from randomized clinical trials. To supplement …

Abstract Background The direct factor Xa inhibitor rivaroxaban is approved for the treatment
of venous thromboembolism (VTE), based on the results of large phase III trials. Objectives …

We investigated three-month clinical outcomes in patients with venous thromboembolism
(VTE) treated with rivaroxaban or conventional anticoagulation in routine clinical practice …

Anticoagulation therapy is essential for the treatment and second prevention of venous
thromboembolism (VTE), including pulmonary embolism (PE) and deep vein thrombosis …

Introduction Randomized clinical trials have demonstrated non-inferiority of rivaroxaban
compared with vitamin K antagonists (VKAs) in the treatment of venous thromboembolism …